Lista de obras - Roberta D'Ambrosio - Dominio Público Uruguay

A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis

artículo científico publicado en 2012

A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: The interferon-inducible gene IFI16

article

Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: case study

artículo científico publicado en 2014

Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review.

artículo científico publicado en 2013

Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.

artículo científico publicado en 2015

Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19

artículo científico publicado en 2020

Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort

artículo científico publicado en 2020

Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease

artículo científico publicado en 2015

De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).

artículo científico

Do ITPA gene variants provide insight to detecting patients infected with HCV 2/1 recombinant strains?

artículo científico publicado en 2015

Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?

artículo científico publicado en 2016

Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity.

artículo científico publicado en 2015

Hepatocellular Carcinoma Risk, Outcomes, and Screening After Hepatitis C Eradication

artículo científico publicado en 2021

Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy

artículo científico publicado en 2015

High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study

artículo científico publicado en 2019

Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.

artículo científico publicado en 2013

Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C.

artículo científico publicado en 2014

Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.

artículo científico publicado en 2012

Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir

artículo científico publicado en 2014

Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B.

artículo científico publicado en 2013

Persistence of hepatocellular carcinoma risk in hepatitis c patients with a response to ifn and cirrhosis regression

artículo científico publicado en 2018

Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis

scientific article published on 30 August 2019

Proteomics to Predict Hepatitis C Therapy Outcome: Where Do We Stand?

artículo científico publicado en 2012

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

artículo científico publicado en 2009

Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients.

artículo científico publicado en 2011

Safety of direct antiviral agents in real life

artículo científico

Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.

artículo científico publicado en 2016

Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?

artículo científico publicado en 2016

Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy.

artículo científico publicado en 2015

Suboptimal accuracy of GES score to stratify Post-SVR HCC risk in a single center cohort of European cirrhotics infected with any HCV genotype

artículo científico publicado en 2020

Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.

artículo científico publicado en 2012

Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis

artículo científico publicado en 2013

The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent

artículo científico publicado en 2014

The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.

artículo científico publicado en 2006

The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.

artículo científico publicado en 2011

Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients

artículo científico publicado en 2015

Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir.

artículo científico publicado en 2012

Treatment of patients with HCV related cirrhosis: many rewards with very few risks.

artículo científico publicado en 2012

Lista de obras de Roberta D'Ambrosio

A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis

A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: The interferon-inducible gene IFI16

Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: case study

Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review.

Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.

Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19

Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort

Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease

De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).

Do ITPA gene variants provide insight to detecting patients infected with HCV 2/1 recombinant strains?

Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?

Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity.

Hepatocellular Carcinoma Risk, Outcomes, and Screening After Hepatitis C Eradication

Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy

High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study

Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.

Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C.

Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.

Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir

Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B.

Persistence of hepatocellular carcinoma risk in hepatitis c patients with a response to ifn and cirrhosis regression

Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis

Proteomics to Predict Hepatitis C Therapy Outcome: Where Do We Stand?

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients.

Safety of direct antiviral agents in real life

Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.

Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?

Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy.

Suboptimal accuracy of GES score to stratify Post-SVR HCC risk in a single center cohort of European cirrhotics infected with any HCV genotype

Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.

Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis

The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent

The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.

The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.

Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients

Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir.

Treatment of patients with HCV related cirrhosis: many rewards with very few risks.